BR0312257A - Composto, composição farmacêutica, processo para a preparação da mesma, e, método de tratamento de um indivìduo sofrendo de um distúrbio mediado pelo receptor de mch1, e de um indivìduo sofrendo de depressão, ansiedade, incontinência urinária, ou obesidade - Google Patents

Composto, composição farmacêutica, processo para a preparação da mesma, e, método de tratamento de um indivìduo sofrendo de um distúrbio mediado pelo receptor de mch1, e de um indivìduo sofrendo de depressão, ansiedade, incontinência urinária, ou obesidade

Info

Publication number
BR0312257A
BR0312257A BR0312257-3A BR0312257A BR0312257A BR 0312257 A BR0312257 A BR 0312257A BR 0312257 A BR0312257 A BR 0312257A BR 0312257 A BR0312257 A BR 0312257A
Authority
BR
Brazil
Prior art keywords
compound
individual suffering
depression
pharmaceutical composition
individual
Prior art date
Application number
BR0312257-3A
Other languages
English (en)
Inventor
Mohammad Marzabadi
Yu Jiang
Kai Lu
Chien-An Chen
John Deleon
John Wetzel
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR0312257A publication Critical patent/BR0312257A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, PROCESSO PARA A PREPARAçãO DA MESMA, E, MéTODOS DE TRATAMENTO DE UM INDIVìDUO SOFRENDO DE UM DISTúRBIO MEDIADO PELO RECEPTOR DE MCH1, E DE UM INDIVìDUO SOFRENDO DE DEPRESSãO, ANSIEDADE, INCONTINêNCIA URINáRIA, OU OBESIDADE". Esta invenção refere-se aos compostos que são antagonistas seletivos para receptores de hormónio-1 concentrador de melanina (MCH1). A invenção proporciona uma composição farmacêutica compreendendo uma quantidade terapeuticamente efetiva do composto da invenção e um veículo farmaceuticamente aceitável. Esta invenção proporciona uma composição farmacêutica preparada pela combinação de uma quantidade terapeuticamente efetiva de composto desta invenção e um veículo farmaceuticamente aceitável. Esta invenção proporciona adicionalmente um processo para a preparação de uma composição farmacêutica compreendendo a combinação de uma quantidade terapeuticamente efetiva de composto da invenção e um veículo farmaceuticamente aceitável. Esta invenção também proporciona um método de redução da massa corporal de um indivíduo que compreende a administração ao indivíduo de uma quantidade de um composto da invenção efetiva para reduzir a massa corporal do indivíduo. Esta invenção proporciona adicionalmente um método de tratamento de um indivíduo sofrendo de depressão e/ou de ansiedade que compreende a administração ao indivíduo de uma quantidade de um composto da invenção efetiva para tratar a depressão e/ou a ansiedade do indivíduo. Esta invenção proporciona adicionalmente um método de tratamento de um indivíduo sofrendo de distúrbio urinário.
BR0312257-3A 2002-07-03 2003-07-03 Composto, composição farmacêutica, processo para a preparação da mesma, e, método de tratamento de um indivìduo sofrendo de um distúrbio mediado pelo receptor de mch1, e de um indivìduo sofrendo de depressão, ansiedade, incontinência urinária, ou obesidade BR0312257A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18914502A 2002-07-03 2002-07-03
PCT/US2003/021391 WO2004005257A1 (en) 2002-07-03 2003-07-03 Secondary amino anilinic piperidines as mch1 antagonists and uses thereof

Publications (1)

Publication Number Publication Date
BR0312257A true BR0312257A (pt) 2005-04-12

Family

ID=30114020

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312257-3A BR0312257A (pt) 2002-07-03 2003-07-03 Composto, composição farmacêutica, processo para a preparação da mesma, e, método de tratamento de um indivìduo sofrendo de um distúrbio mediado pelo receptor de mch1, e de um indivìduo sofrendo de depressão, ansiedade, incontinência urinária, ou obesidade

Country Status (18)

Country Link
US (1) US7473698B2 (pt)
EP (1) EP1556351A4 (pt)
JP (1) JP2005532399A (pt)
KR (1) KR20050034710A (pt)
CN (1) CN1319945C (pt)
AU (1) AU2003259098A1 (pt)
BR (1) BR0312257A (pt)
CA (1) CA2485379A1 (pt)
EA (1) EA008826B1 (pt)
IL (1) IL165730A0 (pt)
IS (1) IS7560A (pt)
MX (1) MXPA04012103A (pt)
NO (1) NO20050113L (pt)
NZ (1) NZ536329A (pt)
PL (1) PL373621A1 (pt)
UA (1) UA77536C2 (pt)
WO (1) WO2004005257A1 (pt)
ZA (1) ZA200409425B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105544B2 (en) 2001-07-05 2006-09-12 Synaptic Pharmaceutical Corporation Substituted alkyl amido piperidines
US7199135B2 (en) 2001-07-05 2007-04-03 H. Lundbeck A/S Substituted alkyl amido piperidines
US20050154022A1 (en) * 2004-01-14 2005-07-14 H. Lundbeck A/S 4-aryl piperidines
US20050154020A1 (en) * 2004-01-14 2005-07-14 Synaptic Pharmaceutical Corporation 4-Aryl piperidines
WO2006015279A1 (en) * 2004-07-28 2006-02-09 Neurogen Corporation Heterocyclic diamine compounds as ligands of the melanin concentrating hormone receptor useful for the treatment of obesity, diabetes, eating and sexual disorders
US7446204B2 (en) 2004-10-08 2008-11-04 H. Lundbeck A/S Amino substituted aryloxybenzylpiperidine derivatives
US20060079683A1 (en) * 2004-10-08 2006-04-13 Marzabadi Mohammad R Arylthiobenzylpiperidine derivatives
US7329656B2 (en) 2004-10-08 2008-02-12 H. Lundbeck A/S Arylthiobenzylpiperidine derivatives
US9452980B2 (en) * 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
WO2017157873A1 (en) 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
FR2744448B1 (fr) 1996-02-02 1998-04-24 Pf Medicament Nouvelles piperidines derivees d'aryl piperazine, ainsi que leur procede de preparation, les compositions pharmaceutiques et leur utilisation comme medicaments
TW548271B (en) * 1996-12-20 2003-08-21 Astra Pharma Inc Novel piperidine derivatives having an exocyclic double bond with analgesic effects
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
US6326381B1 (en) * 1998-12-17 2001-12-04 American Home Products Corporation Arylpiperidine and aryl-1,2,5,6-tetrahydropyidine amide derivates
US20030082623A1 (en) * 1998-12-31 2003-05-01 Beth Borowsky DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
EP1299362A4 (en) * 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
JP2004502423A (ja) * 2000-07-05 2004-01-29 シナプティック・ファーマスーティカル・コーポレーション ヒトメラニン濃縮ホルモン受容体（ｍｃｈ１）をコードするｄｎａ及びその使用
IL158941A0 (en) 2001-05-22 2004-05-12 Neurogen Corp Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
EP1411942A4 (en) 2001-07-05 2005-01-26 Synaptic Pharma Corp SUBSTITUTED ANILINPIPERIDINES AS MCH-SELECTIVE ANTAGONISTS

Also Published As

Publication number Publication date
CN1665786A (zh) 2005-09-07
UA77536C2 (en) 2006-12-15
US20050245743A1 (en) 2005-11-03
PL373621A1 (en) 2005-09-05
EA200500152A1 (ru) 2005-06-30
US7473698B2 (en) 2009-01-06
AU2003259098A1 (en) 2004-01-23
JP2005532399A (ja) 2005-10-27
CN1319945C (zh) 2007-06-06
KR20050034710A (ko) 2005-04-14
MXPA04012103A (es) 2005-04-19
NO20050113L (no) 2005-01-10
WO2004005257A1 (en) 2004-01-15
IL165730A0 (en) 2006-01-15
IS7560A (is) 2004-11-26
EP1556351A1 (en) 2005-07-27
HK1080471A1 (en) 2006-04-28
CA2485379A1 (en) 2004-01-15
ZA200409425B (en) 2006-04-26
NZ536329A (en) 2007-06-29
EA008826B1 (ru) 2007-08-31
EP1556351A4 (en) 2007-07-25

Similar Documents

Publication Publication Date Title
BR0312256A (pt) Composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, e, método de tratamento de um indivìduo sofrendo de um distúrbio mediado pelo receptor de mch1 e de tratamento de um indivìduo sofrendo de depressão, ansiedade, incontinência de urgência ou obesidade
BRPI0406725A (pt) Composto, composição farmacêutica, processo para preparar a mesma, e, métodos para tratar um indivìduo sofrendo de um distúrbio afetivo, para tratar um indivìduo sofrendo de um distúrbio urinário e para tratar um indivìduo sofrendo de um distúrbio de alimentação
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
AP1542A (en) Glucocorticoid receptor modulators.
DE60231341D1 (de) Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten
BR0312257A (pt) Composto, composição farmacêutica, processo para a preparação da mesma, e, método de tratamento de um indivìduo sofrendo de um distúrbio mediado pelo receptor de mch1, e de um indivìduo sofrendo de depressão, ansiedade, incontinência urinária, ou obesidade
WO2002053177A3 (en) Agents and methods for treating pain
GR1002466B (el) Νεες ενωσεις.
BRPI0417156A (pt) composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
MY121054A (en) Calcilytic compounds as calcium receptor antagonists.
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
WO2000048581A3 (en) Use of 5-ht3 receptor antagonists for treating musculoeskeletal diseases
UA77025C2 (en) Tetrahydrocarbozole derivatives as ligands for g-protein coupled receptors (gpcr), a pharmaceutical composition and a method for preparation of compounds
WO2006035282A3 (en) Muscarinic receptor antagonists
YU60803A (sh) Upotreba antagonista gal3 receptora u lečenju depresije i/ili uznemirenosti i jedinjenja korisna u tim postupcima
BRPI0816571A2 (pt) "composto, processo para preparação do composto, composição farmacêutica, agente e método para o tratamento de uma doença ou uma desordem do sistema nervoso central relacionada à ou afetada pelo recptor 5-ht6"
EA200601315A1 (ru) 4-арилпиперидины
WO2000004012A8 (en) COMPOUNDS SPECIFIC FOR THE HUMAN α1d ADRENERGIC RECEPTOR AND USES THEREOF
BR0210869A (pt) Composto, composição farmacêutica, processo de preparar uma composição farmacêutica, métodos de tratar um indivìduo que sofre de um distúrbio, de depressão e de ansiedade, obesidade, bexiga hiperativa e um distúrbio em um indivìduo, de reduzir a massa corporal de um indivìduo e de aliviar incontinência de urgência urinária e os sintomas de um distúrbio em um indivìduo
WO2000076457A3 (en) Il-8 receptor antagonists
WO2006041636A3 (en) Amino substituted aryloxybenzylpiperidine derivatives
WO2006041635A3 (en) Arylthiobenzylpiperidine derivatives
WO2004034967A3 (en) 2,4,6-triaminopyrimidines for the treatment of depression and/or anxiety

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2116 DE 26/07/2011.